KPTI

Karyopharm Therapeutics Inc

• TipRanks·5d ago

  Karyopharm (KPTI) Leans on SENTRY in Pivotal Call

• Benzinga·5d ago

  12 Health Care Stocks Moving In Tuesday's Pre-Market Session

• PUBT·6d ago

  Karyopharm publishes corporate presentation highlighting selinexor Phase 3 trial readouts in 2026

• Simply Wall St·05/15 23:41

  Karyopharm Therapeutics (KPTI) Quarterly Loss Deepens Reinforcing Bearish Profitability Concerns

• TipRanks·05/15 15:26

  Leerink Partners Sticks to Its Hold Rating for Karyopharm Therapeutics (KPTI)

• TipRanks·05/15 11:48

  RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)

• TipRanks·05/15 00:20

  Karyopharm Earnings Call: Trial Wins, Cash Questions

• Seeking Alpha·05/14 19:01

  Karyopharm outlines $130M-$150M 2026 revenue outlook as it prepares mid-2026 XPORT-EC-042 readout

• The Motley Fool·05/14 18:20

  Karyopharm (KPTI) Q1 2026 Earnings Transcript

• Benzinga·05/14 13:37

  Karyopharm Therapeutics Reports Q1 2026 Results: Full Earnings Call Transcript

• TipRanks·05/14 12:06

  Karyopharm reports Q1 EPS ($1.24), consensus ($1.44)

• TipRanks·05/14 12:04

  Karyopharm sees 2026 revenue $130M-$150M, consensus $137.49M

• PUBT·05/14 11:47

  Karyopharm Q1 FY26 operating loss narrows 20% to $26.76 million; revenue rises 17% to $35.07 million

• Reuters·05/14 11:42

  Karyopharm Q1 net loss narrows

• Seeking Alpha·05/14 11:39

  Karyopharm Therapeutics GAAP EPS of -$1.24 beats by $0.25, revenue of $35.07M beats by $3.67M